Vol. 11 No. 2 (2019): Archives of Public Health
Clinical Science

Sociodemographic characteristics and thrombophilic mutations in women with in vitro fertilization failure – initial results from case control study

Elena Petkovikj
Institute of transfusion medicine, Skopje, Republic of North Macedonia
Anita Hristova Dimceva
Institute of transfusion medicine, Skopje, Republic of North Macedonia
Rada Grubovic Rastvorceva
Institute of transfusion medicine, Skopje, Republic of North Macedonia
Sedula Useini
Institute of transfusion medicine, Skopje, Republic of North Macedonia

Published 2019-08-22


  • thrombophilia,
  • factor V Leiden,
  • methylentetrahydrofolate reductase,
  • prothrombin,
  • IVF failure

How to Cite

Petkovikj E, Hristova Dimceva A, Grubovic Rastvorceva R, Useini S. Sociodemographic characteristics and thrombophilic mutations in women with in vitro fertilization failure – initial results from case control study. Arch Pub Health [Internet]. 2019 Aug. 22 [cited 2024 Apr. 16];11(2):19-25. Available from: https://www.id-press.eu/aph/article/view/4195


There are many factors for in vitro fertilization (IVF) failure, and hereditary thrombophilia has been mentioned as one of them in the last few years. Thrombophilia is a condition of predisposition to thromboembolism. The aim of the study was to evaluate the sociodemographic characteristics and to examine the representation of thrombophilic mutations in women with IVF failure. Material and methods: In a retrospective-prospective case-control study we evaluated 52 women, divided in two groups. Twenty-twowomen with at least three IVF failures were included in the examined group (EG). Thirty women, age matched, who gave birth to at least one healthy child without obstetric complications were included in the control group. Presence of gene mutations for factor II Prothrombin (G20210A), factor V Leiden (FVL) and methylentetrahydrofolate reductase (MTHFR C677T) was examined in both groups. Sociodemographic data, data from personal, family and obstetric anamnesis was collected with standard questionnaire. Results: Representation of nationality in both groups roughly corresponds to the national structure in Republic of Macedonia. In both groups the most prevalent age was from 30 to 34 years (40% in the CG and 50% in the EG). According to the degree of education, homogeneity between the two groups was registered. In most of the EG, MTHFR heterozygous was 63.6% vs. 56.7% in the CG, followed by the FV Leiden heterozygous with 13.6% vs. 3.3% in the CG, MTHFR homozygous with 9.1% vs. 6.7% in CG, factor II Prothrombin (G20210A) heterozygous with 4.5% vs. 6.7 in CG. 72.7% of women in the EG and 60% in the CG had one thrombophilic mutation, and 9.1% of women in EG and 6.7% in CG had two thrombophilic mutations. 18.2% of women in EG and 33.3% in CG did not have any mutations. Conclusion: The sociodemographic profile of women with IVF failure is a woman aged between 30 and 34 years with a university degree, with at least one thrombophilic mutation. Thrombophilic mutation has not been registered in only a small percentage of women with failed IVF.


Download data is not yet available.


  1. Simon A, Laufer N. Repeated implantation failure: clinical approach. Fertil Steril 2012; 97:1039-1043.
  2. Fukui A, Funamizu A, Yokota M, Yamada K, Nakamua R, Fukuhara R, et al. Uterine and circulating natural killer cells and their roles in women with recurrent pregnancy loss, implantation failure and preeclampsia. J Reprod Immunol 2011;90:105–10.
  3. Margalioth EJ, Ben-Chetrit A, Gal M, Eldar-Geva T. Investigation and treatment of repeated implantation failure following IVF-ET. Hum Reprod 2006; 21:3036–43.
  4. Tan BK, Vandekerckhove P, Kennedy R and Keay SD. Investigation and current management of recurrent IVF treatment failure in the UK. BJOG 2005; 112(6):773-780.
  5. Scott L. Embryological strategies for overcoming recurrent assisted reproductive technology treatment failure. Hum Fertil 2002; 5: 206-214.
  6. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L, Greer IA; Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006;132(2): 171-96.
  7. Lockwood CJ. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002;99(2):333-41.
  8. Vucić N, Frleta M, Petrović D, Ostojić V. Thrombophilia, preeclampsia and other pregnancy complications. Acta Med Croatica 2009; 63(4):297-305.
  9. Kujovich JL. Factor V Leiden thrombophilia. Genetics in medicine 2011; 13: 1-16.
  10. Azem F, Many A, Ben Ami I, et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19: 368-370.
  11. Grandone E, Colaizzo D, Lo Bue A, Checola MG, Cittadini E, Margaglione M. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril 2001;76: 201–202.
  12. Martinelli I, Taiolo E, Ragni G, et al. Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica 2003; 88: 789–793.
  13. Di Nisio M, Rutjes AWS, Ferrante N, Tiboni GM, Cucurullo F, Porreca E. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood 2011; 18:2670-2678.